James Richardson is an Infectious Disease physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Rosalind Redfern Grover Pkwy Ste 230
Midland, TX 797015856
Telephone
432-221-3200Provider last certified this registry record 7 Mar 2025.
Clinical trials
- Autologous Stem Cell Therapy for Fracture Non-union Healing
Sponsor: Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year202516 payments
- Gilead Sciences, Inc.Program year20258 payments
- Merck Sharp & Dohme LLCProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
85.9%Tetracycline-class Drug15.3%Doxycycline Hyclate100%Part D≥45 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor12.9%Triumeq86%Abacavir14%Part D<11 patients+ 8 more classes in this area
Dermatology
5.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor3.4%Acyclovir100%Part D<11 patientsAzole Antifungal2.1%Clotrimazole100%Part D<11 patientsNervous system
4%Nonsteroidal Anti-inflammatory Drug4%Meloxicam100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1995–2006 per NIH RePORTER. The latest:
- CORE--MICROSCOPY AND IMMUNOHISTOCHEMISTRY
University of Texas Sw Med Ctr/dallas
FY2005$374,195P01HL006296 - CORE--MICROSCOPY AND IMMUNOHISTOCHEMISTRY
University of Texas Sw Med Ctr/dallas
FY2002$344,414P01HL006296
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”